Compare Amylx Pharmaceuticals Inc (AMLX) vs Rush Street Interactive Inc (RSI) Price & Performance

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Rush Street Interactive (RSI) trades at $25.08, up 1.46% today, with a bearish technical signal but strong analyst support. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Despite a high P/E ratio of 81.13, profitability metrics like a 20.72% ROE and recent earnings beats signal operational strength. Key resistance sits at $26, with support near $24.

The outlook is positive driven by revenue growth and market expansion, but high valuation and mixed technicals pose risks. Analyst consensus is bullish with a $34.75 price target, though regulatory pressures in the gaming sector remain a concern. The stock offers growth potential but requires monitoring of execution and market sentiment.